<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1d3" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">65131</article-id><article-id pub-id-type="doi">10.7554/eLife.65131</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Epidemiology and Global Health</subject></subj-group></article-categories><title-group><article-title>Efficacy profile of the CYD-TDV dengue vaccine revealed by Bayesian survival analysis of individual-level Phase III data</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="author-216050"><name><surname>Laydon</surname><given-names>Daniel J</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-4270-3321</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="cor1">*</xref><xref ref-type="other" rid="par-1"/><xref ref-type="other" rid="par-2"/><xref ref-type="other" rid="par-3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-141741"><name><surname>Dorigatti</surname><given-names>Ilaria</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-9959-0706</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="par-3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-218644"><name><surname>Hinsley</surname><given-names>Wes R</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="par-3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-218645"><name><surname>Nedjati-Gilani</surname><given-names>Gemma L</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="par-1"/><xref ref-type="other" rid="par-2"/><xref ref-type="other" rid="par-3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-218646"><name><surname>Coudeville</surname><given-names>Laurent</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-228970"><name><surname>Ferguson</surname><given-names>Neil M</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="other" rid="par-1"/><xref ref-type="other" rid="par-2"/><xref ref-type="other" rid="par-3"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><institution content-type="dept">Department of Infectious Disease Epidemiology, MRC Centre for Global Infectious Disease Analysis</institution>, <institution>Imperial College London</institution>, <addr-line><named-content content-type="city">London</named-content></addr-line>, <country>United Kingdom</country></aff><aff id="aff2"><institution content-type="dept">Infectious Disease Epidemiology</institution>, <institution>Imperial College London</institution>, <addr-line><named-content content-type="city">London</named-content></addr-line>, <country>United Kingdom</country></aff><aff id="aff3"><institution content-type="dept">Sanofi-Pasteur</institution>, <institution>Sanofi-Pasteur</institution>, <addr-line><named-content content-type="city">Lyon</named-content></addr-line>, <country>France</country></aff><aff id="aff4"><institution content-type="dept">MRC Centre for Global Infectious Disease Analysis, Department of Infectious Disease Epidemiology</institution>, <institution>Imperial College London</institution>, <addr-line><named-content content-type="city">London</named-content></addr-line>, <country>United Kingdom</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor" id="author-34498"><name><surname>Cooper</surname><given-names>Ben S</given-names></name><role>Reviewing editor</role><aff><institution>Mahidol University</institution>, <country>Thailand</country></aff></contrib></contrib-group><author-notes><corresp id="cor1"><label>*</label>For correspondence: <email>d.laydon@imperial.ac.uk</email> (DL);</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>02</day><month>07</month><year>2021</year></pub-date><volume>10</volume><elocation-id>e65131</elocation-id><history><date date-type="received"><day>24</day><month>11</month><year>2020</year></date><date date-type="accepted"><day>29</day><month>06</month><year>2021</year></date></history><permissions><copyright-statement>© 2021, Laydon et al</copyright-statement><copyright-year>2021</copyright-year><copyright-holder>Laydon et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link> permitting unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-65131-v1.pdf"/><abstract><p><bold>Background:</bold> Sanofi-Pasteur’s CYD-TDV is the only licensed dengue vaccine. Two phase III trials showed higher efficacy in seropositive than seronegative recipients. Hospital follow-up revealed increased hospitalisation in 2-5-year-old vaccinees, where serostatus and age effects were unresolved.</p><p><bold>Methods:</bold> We fit a survival model to individual-level data from both trials, including year one of hospital follow-up. We determine efficacy by age, serostatus, serotype and severity, and examine efficacy duration and vaccine action mechanism.</p><p><bold>Results:</bold> Our modelling indicates that vaccine-induced immunity is long-lived in seropositive recipients, and therefore that vaccinating seropositives gives higher protection than two natural infections. Long-term increased hospitalisation risk outweighs short-lived immunity in seronegatives. Independently of serostatus, transient immunity increases with age, and is highest against serotype 4. Benefit is higher in seropositives, and risk enhancement is greater in seronegatives, against hospitalised disease than febrile disease.</p><p><bold>Conclusions:</bold> Our results support vaccinating seropositives only. Rapid diagnostic tests would enable viable “screen-then-vaccinate” programs. Since CYD-TDV acts as a silent infection, long-term safety of other vaccine candidates must be closely monitored.</p><p><bold>Funding:</bold> Bill and Melinda Gates Foundation, National Institute for Health Research, UK Medical Research Council, Wellcome Trust.</p></abstract><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd><kwd>Viruses</kwd></kwd-group><funding-group><award-group id="par-1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000865</institution-id><institution>Bill and Melinda Gates Foundation</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Laydon</surname><given-names>Daniel J</given-names></name><name><surname>Nedjati-Gilani</surname><given-names>Gemma L</given-names></name><name><surname>Ferguson</surname><given-names>Neil M</given-names></name></principal-award-recipient></award-group><award-group id="par-2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000272</institution-id><institution>National Institute for Health Research</institution></institution-wrap></funding-source><award-id>NIHR: PR-OD-1017-20002</award-id><principal-award-recipient><name><surname>Laydon</surname><given-names>Daniel J</given-names></name><name><surname>Nedjati-Gilani</surname><given-names>Gemma L</given-names></name><name><surname>Ferguson</surname><given-names>Neil M</given-names></name></principal-award-recipient></award-group><award-group id="par-3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000265</institution-id><institution>Medical Research Council</institution></institution-wrap></funding-source><award-id>MR/R015600/1</award-id><principal-award-recipient><name><surname>Laydon</surname><given-names>Daniel J</given-names></name><name><surname>Dorigatti</surname><given-names>Ilaria</given-names></name><name><surname>Hinsley</surname><given-names>Wes R</given-names></name><name><surname>Nedjati-Gilani</surname><given-names>Gemma L</given-names></name><name><surname>Ferguson</surname><given-names>Neil M</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group></article-meta></front><back><sec id="s1" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interest</title><fn fn-type="conflict" id="conf2"><p>Laurent Coudeville, Laurent Coudeville is employed by Sanofi-Pasteur.</p></fn><fn fn-type="conflict" id="conf1"><p>The other authors declare that no competing interests exist.</p></fn></fn-group></sec><sec id="s2" sec-type="supplementary-material"><title>Additional Files</title><sec id="s3" sec-type="data-availability"><title>Data availability</title><p>Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at:  https://www.clinicalstudydatarequest.com. Additional details of the trial designs and data can be found in Sridhar et al (NEJM 2018).All model code is available at https://github.com/dlaydon/DengVaxSurvival, which is linked to in the manuscript. This repository also contains simulated data, generated to closely match the trial data, giving comparable case numbers across strata. When our model is fitted to the simulated data, the resulting parameter estimates closely approximate the results presented in this analysis.</p></sec><supplementary-material><ext-link xlink:href="elife-65131-supp-v1.zip">Download zip</ext-link><p>Any figures and tables for this article are included in the PDF. The zip folder contains additional supplemental files.</p></supplementary-material></sec></back></article>